Abatacept

• Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis

Abatacept is a selective T-cell co-stimulation modulator used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. As a biologic disease-modifying antirheumatic drug (DMARD), abatacept offers a unique mechanism for controlling autoimmune inflammation by targeting a critical step in T-cell activation.

Mechanism of Action

Abatacept is a fusion protein consisting of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1. It works by binding to CD80 and CD86 receptors on antigen-presenting cells, thereby blocking the CD28-mediated co-stimulatory signal required for full T-cell activation. Without this second signal, T-cells become anergic or undergo apoptosis rather than mounting an inflammatory response. This selective modulation of T-cell activation reduces the downstream production of inflammatory cytokines including TNF-alpha, interleukin-2, and interferon-gamma, ultimately decreasing joint inflammation and damage.

Available Formulations

Abatacept is available in two formulations: an intravenous (IV) infusion and a subcutaneous (SC) injection. The IV formulation comes as a lyophilized powder requiring reconstitution, available in 250 mg vials. The SC formulation is available as prefilled syringes and autoinjectors containing 125 mg/mL. Both formulations have demonstrated similar efficacy in clinical trials.

Medical Uses

Abatacept is approved for treating moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more DMARDs. It can be used as monotherapy or in combination with other DMARDs (except TNF antagonists). The medication is also approved for polyarticular juvenile idiopathic arthritis in patients 2 years and older and for active psoriatic arthritis in adults. Clinical trials have shown significant improvements in joint symptoms, physical function, and inhibition of structural damage progression.

Dosing Guidelines

For IV administration, dosing is weight-based: patients under 60 kg receive 500 mg, those 60-100 kg receive 750 mg, and those over 100 kg receive 1000 mg. Infusions are given at weeks 0, 2, and 4, then every 4 weeks thereafter. For SC administration, patients receive 125 mg weekly following an optional IV loading dose. Patients transitioning from IV to SC should administer their first SC dose instead of the next scheduled IV dose.

Important Safety Information

Abatacept should not be administered concurrently with TNF antagonists or other biologic DMARDs due to increased infection risk without added benefit. Patients should be screened for latent tuberculosis and hepatitis B before starting therapy. Live vaccines should be avoided during treatment and for 3 months after discontinuation. The medication may increase the risk of serious infections, particularly in patients with a history of recurrent infections or underlying conditions predisposing to infections.

Drug Interactions

Concurrent use with TNF antagonists (etanercept, infliximab, adalimumab) or other biologic DMARDs is contraindicated due to increased serious infection risk. Abatacept may be used with methotrexate, other non-biologic DMARDs, corticosteroids, and NSAIDs. Blood glucose monitoring may be affected in patients using glucose monitors with test strips containing maltose.

Special Populations

Abatacept crosses the placenta and should be used during pregnancy only if clearly needed. Women of childbearing potential should use effective contraception during treatment and for 14 weeks after the last dose. The medication is excreted in breast milk in animals; the decision to breastfeed should consider the importance of the drug to the mother. Elderly patients may have increased susceptibility to infections and should be monitored closely.